اكتشف أفضل عيادات وتكاليف العلاج علاج مرض السكري بالخلايا الجذعية في إيطاليا 2026

Stem cell therapies for diabetes are not yet approved for routine clinical use in Italy. These treatments remain strictly limited to clinical trials and experimental protocols under the Italian Medicines Agency (AIFA). Standard practice still relies on whole pancreas or donor islet transplants rather than stem cells.

• Regulatory status: Classified as Advanced Therapy Medicinal Products (ATMPs) requiring European Medicines Agency (EMA) approval.
• Clinical research: Major trials occur at San Raffaele Research Hospital (IRCCS) in Milan.
• Authorized institutions: Only IRCCS-accredited centers can legally conduct these specialized regenerative research protocols.
• Future timeline: Experts anticipate potential regulatory approvals for routine use beginning around late 2026.

Bookimed Expert Insight: San Raffaele Research Hospital holds a unique advantage as the world's first center to achieve approved stem cell therapy for other conditions. While diabetes treatments are experimental, this institutional experience ensures trials follow the highest safety protocols. Patients should prioritize these accredited research centers over private clinics to ensure clinical oversight.

Patient Consensus: Many patients emphasize that stem cell therapy is not a permanent cure. Most report insulin independence lasts about 1.5 years before needing standard backup medical technology again.

Main safety risks include tumor formation from undifferentiated cells and immune system rejection of transplanted material. Patients may also face inappropriate cell differentiation or vascular blockages from intravenous infusions. Medical facilities in Italy, like San Raffaele, prioritize IRCCS-accredited research standards to mitigate these serious clinical complications.

• Tumorigenicity risks: Pluripotent cells may form teratomas if they differentiate incorrectly during processing.
• Immune rejection: The immune system may attack new cells, causing graft failure or inflammation.
• Ectopic formation: Stem cells can transform into unintended tissues like bone in pancreatic sites.
• Vascular safety: Intravenous injections carries risks of blood clots or pulmonary embolisms.
• Infection control: Procedural contamination during cell harvesting can lead to viral or bacterial infections.

Bookimed Expert Insight: Safety significantly increases at Italian IRCCS research hospitals like San Raffaele in Milan. These centers hold Ministry of Health accreditation for genetic research. Choosing an academic facility over a private boutique clinic ensures adherence to rigorous EU clinical trial protocols. This oversight is vital as most diabetes stem cell treatments remain experimental worldwide.

Patient Consensus: Many patients emphasize the need to verify trial registration on the EU Clinical Trials Register. Others report severe fatigue or allergic responses and suggest keeping an endocrinologist involved throughout.

Italian and international clinical trials demonstrate improved diabetes control through automated technology, advanced drug therapies, and intensive metabolic interventions. Studies highlight Automated Insulin Delivery (AID) and weekly basal insulin as primary drivers in stabilizing HbA1c levels and increasing time in target glucose ranges.

• Technological impact: AID systems increased children's time in glucose range by 5.45% within six months.
• Pharmacological progress: Fixed-dose combinations helped 40.3% of patients reach target HbA1c levels of under 7%.
• Therapeutic frequency: New weekly basal insulin reduced annual injections from 365 to only 52 doses.
• Remission potential: Mediterranean diet research showed partial remission in over 10% of newly diagnosed subjects.

Bookimed Expert Insight: Italy’s leadership in diabetes research is anchored by IRCCS-accredited centers like San Raffaele in Milan. These institutions operate as research hospitals, bridging the gap between clinical trials and bedside care. While stem cell protocols are emerging, the immediate benefit for patients lies in the integration of specialized technology within these research-heavy environments.

Ospedale San Raffaele in Milan leads Italian stem cell trials for diabetes through its Diabetes Research Institute. This IRCCS-accredited center conducts high-priority Phase 1/2 studies on allogeneic islet infusions and CRISPR-engineered immune-evasive cells. Other key sites include Galeazzi-Sant'Ambrogio and research hubs in Turin.

• Ospedale San Raffaele: Participating in international multicenter trials for stem-cell-derived islet cell infusions.
• San Donato hospital: Provides diagnostic evaluation and personalized clinical screening for regenerative therapy candidates.
• Galeazzi-Sant'Ambrogio: Operates the RE.GA.IN Institute, a government-approved facility for advanced cell handling.
• Continuity biosciences: Developing the NICHE bioengineered platform in Turin to protect implanted cells.

Bookimed Expert Insight: While San Raffaele handles over 300,000 patients yearly, their IRCCS status is the critical differentiator. This Italian Ministry of Health accreditation confirms they legally combine clinical assistance with active research. For patients, this means direct access to trials that private clinics cannot legally provide.

Patient Consensus: Patients emphasize verifying any Italian stem cell trial through official clinical registries before booking. Local communities warn about high costs and advise consulting endocrinologists to manage expectations regarding long-term results.

The Italian National Health Service (SSN) does not currently reimburse stem cell therapy for diabetes. While Italy covers stem cell treatments for specific hematological and genetic conditions, diabetes therapy remains experimental. The Italian Medicines Agency (AIFA) has not approved it for national reimbursement coverage.

• Standard coverage: Public funding focuses on insulin, glucose monitors, and GLP-1 receptor agonists.
• Clinical trials: Patients may access experimental treatments for free via authorized research hospital trials.
• Pancreatic transplantation: Reimbursed in specific regions like Veneto for high-risk Type 1 diabetes cases.
• Institutional centers: San Raffaele Hospital in Milan conducts advanced cell research for autoimmune conditions.

Bookimed Expert Insight: While national reimbursement is unavailable, San Raffaele Hospital holds IRCCS accreditation from the Italian Ministry of Health. This status confirms their dual role in clinical care and pioneering research. Patients seeking cell-based interventions often find authorized research protocols at such institutions rather than through standard regional scripts. Experience at these centers is high, with San Raffaele performing over 52,000 operations annually across various specialties.

Patient Consensus: Current sentiment reflects the experimental nature of the treatment, with very limited public health coverage available. Patients suggest consulting an endocrinologist directly regarding specific regional policies or eligibility for active research protocols.

Patients enroll in Italian diabetes stem-cell trials by registering through the AIFA National Observatory or the EU Clinical Trials Register. Screening requires a referral from an endocrinologist. Leading centers like San Raffaele Hospital evaluate candidates based on HbA1c levels and pancreatic function.

• Official registry: Search the AIFA National Observatory on Clinical Trials (OsSC) for active Phase I-IV phases.
• Institution contact: Contact the Diabetes Research Institute at San Raffaele for islet cell research trials.
• Medical eligibility: Candidates typically need HbA1c levels under 11% and no active infections.
• Referral process: Obtain a specialist referral and submit medical history to the International Patient Office.

Bookimed Expert Insight: Italian research centers often prioritize patients for gene therapy and stem-cell trials through specialized online second-opinion services. Institutions like San Raffaele use these digital consultations to filter international candidates before physical travel. This saves patients significant costs on preliminary diagnostic travel to Milan or Rome.

Patient Consensus: Patients emphasize that managing expectations regarding trial phases is vital for emotional stability. Most appreciate the thoroughness of Italian screening protocols as a sign of high safety standards.